| An mRNA vaccine against SARS-CoV-2—preliminary report LA Jackson, EJ Anderson, NG Rouphael, PC Roberts, M Makhene, ... New England journal of medicine 383 (20), 1920-1931, 2020 | 3045 | 2020 |
| Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults EJ Anderson, NG Rouphael, AT Widge, LA Jackson, PC Roberts, ... New England Journal of Medicine 383 (25), 2427-2438, 2020 | 1384 | 2020 |
| Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates KS Corbett, B Flynn, KE Foulds, JR Francica, S Boyoglu-Barnum, ... New England Journal of Medicine 383 (16), 1544-1555, 2020 | 993 | 2020 |
| Durability of responses after SARS-CoV-2 mRNA-1273 vaccination AT Widge, NG Rouphael, LA Jackson, EJ Anderson, PC Roberts, ... New England Journal of Medicine 384 (1), 80-82, 2021 | 742 | 2021 |
| Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial PB Gilbert, DC Montefiori, AB McDermott, Y Fong, D Benkeser, W Deng, ... Science 375 (6576), 43-50, 2022 | 684 | 2022 |
| Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19 N Doria-Rose, MS Suthar, M Makowski, S O’Connell, AB McDermott, ... New England Journal of Medicine 384 (23), 2259-2261, 2021 | 627 | 2021 |
| Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants A Pegu, SE O’Connell, SD Schmidt, S O’Dell, CA Talana, L Lai, J Albert, ... Science 373 (6561), 1372-1377, 2021 | 441 | 2021 |
| Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection RM Lynch, E Boritz, EE Coates, A DeZure, P Madden, P Costner, ... Science translational medicine 7 (319), 319ra206-319ra206, 2015 | 425 | 2015 |
| Homologous and heterologous Covid-19 booster vaccinations RL Atmar, KE Lyke, ME Deming, LA Jackson, AR Branche, HM El Sahly, ... New England Journal of Medicine 386 (11), 1046-1057, 2022 | 345 | 2022 |
| Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env Y Do Kwon, M Pancera, P Acharya, IS Georgiev, ET Crooks, J Gorman, ... Nature structural & molecular biology 22 (7), 522-531, 2015 | 340 | 2015 |
| Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag DR Casimiro, F Wang, WA Schleif, X Liang, ZQ Zhang, TW Tobery, ... Journal of virology 79 (24), 15547-15555, 2005 | 307 | 2005 |
| HIV vaccine design: insights from live attenuated SIV vaccines WC Koff, PR Johnson, DI Watkins, DR Burton, JD Lifson, KJ Hasenkrug, ... Nature immunology 7 (1), 19-23, 2006 | 297 | 2006 |
| Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239 NA Wilson, J Reed, GS Napoe, S Piaskowski, A Szymanski, J Furlott, ... Journal of virology 80 (12), 5875-5885, 2006 | 283 | 2006 |
| Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses MG Joyce, AK Wheatley, PV Thomas, GY Chuang, C Soto, RT Bailer, ... Cell 166 (3), 609-623, 2016 | 273 | 2016 |
| Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site M Kanekiyo, W Bu, MG Joyce, G Meng, JRR Whittle, U Baxa, T Yamamoto, ... Cell 162 (5), 1090-1100, 2015 | 261 | 2015 |
| Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults Clinical & Experimental Immunology 182 (3), 289-301, 2015 | 255 | 2015 |
| Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1 K Xu, P Acharya, R Kong, C Cheng, GY Chuang, K Liu, MK Louder, ... Nature medicine 24 (6), 857-867, 2018 | 239 | 2018 |
| Defining B cell immunodominance to viruses D Angeletti, JS Gibbs, M Angel, I Kosik, HD Hickman, GM Frank, SR Das, ... Nature immunology 18 (4), 456-463, 2017 | 208 | 2017 |
| Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase … DH O'Connor, BR Mothe, JT Weinfurter, S Fuenger, WM Rehrauer, P Jing, ... Journal of virology 77 (16), 9029-9040, 2003 | 208 | 2003 |
| A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite NK Kisalu, AH Idris, C Weidle, Y Flores-Garcia, BJ Flynn, BK Sack, ... Nature medicine 24 (4), 408-416, 2018 | 207 | 2018 |
John mascolaNational Institutes of HealthVerified email at mail.nih.gov
